Dyadic Intl Inc Del Stock Price, News & Analysis

Dyadic International (NASDAQ: DYAI), a biotechnology firm, has announced its participation in several key industry events in September 2022. The company will present at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, followed by a panel at the World Health Organization consultation on September 13-14. Additionally, Dyadic will participate in the Vaccine Technology Summit and BioProcess International. The management will be available for one-on-one meetings during these events to discuss their innovative microbial platforms aimed at enhancing global protein production and biopharmaceutical products.

Dyadic International announced the submission of a Clinical Trial Application (CTA) for its DYAI-100 COVID-19 vaccine to South Africa's SAHPRA, marking a significant milestone for its C1-cell protein production platform. The CTA supports a Phase 1 study focusing on safety and efficacy. The company reported cash and investments of $15.7 million as of June 30, 2022, and noted a decrease in revenue and expenses in the second quarter compared to the previous year. A conference call to discuss financial results is scheduled for August 10, 2022, at 5:00 PM EST.

Dyadic International, Inc. (NASDAQ: DYAI) announced it will report its second-quarter 2022 financial results and host a corporate update call on August 10, 2022, at 5:00 p.m. ET. The company focuses on enhancing its proprietary C1-cell protein production platform for biologic vaccines and drugs, aiming to lower costs and improve performance. Investors can access the live conference via provided dial-in numbers and a webcast link. An archive will be available post-event on Dyadic's website.

Dyadic International (NASDAQ: DYAI), a biotechnology company, announced participation in two key industry events this July 2022.

The Bio-Manufacturing Innovation Summit will be held on July 7-8 at Rutgers University, with a presentation by Mark Emalfarb. The NIIMBL 2022 National Meeting is scheduled for July 26-28 in Washington DC, featuring a poster session by Emalfarb.

Dyadic's management will be available for one-on-one meetings during these events. For more details, visit Dyadic's website.

Dyadic International, Inc. (NASDAQ: DYAI) announced its participation in three industry events in June 2022, aimed at advancing its proprietary C1 protein production platform. The events are:

• Vaccine Technology VIII: June 12-17, 2022, Sitges, Spain
• BIO International Convention: June 13-16, 2022, San Diego, CA
• Future Food-Tech Alternative Proteins: June 21-22, 2022, New York, NY

Management will be available for one-on-one meetings. The C1 platform is focused on reducing costs and enhancing the efficacy of biologic vaccines and drugs.

Dyadic International (NASDAQ: DYAI) announced that CEO Mark Emalfarb will present at the 2022 Jefferies Healthcare Conference on June 9, 2022, at 3:00 PM ET. The presentation will showcase Dyadic's proprietary C1-cell protein production platform aimed at enhancing biologic vaccines and drugs. A live webcast will be available for viewing, and a replay will be archived on the company's website. Investors can also arrange one-on-one meetings with the CEO for more detailed discussions.

Dyadic International (NASDAQ: DYAI) announced its participation in the 2022 H.C. Wainwright Global Investment Conference held from May 23-26, 2022, at the Fontainebleau Miami Beach Hotel. President and CEO, Mark Emalfarb, will present on May 25, 2022, at 12:30 PM ET. The management team will also host one-on-one meetings, accessible through a request at hzosiak@dyadic.com. Dyadic focuses on developing its proprietary C1-cell protein production platform to enhance the efficiency and cost-effectiveness of biologic vaccines and drugs.

Dyadic International (NASDAQ: DYAI) reported a 40.8% revenue increase in Q1 2022, reaching approximately $534,000. The company secured a new collaboration with a global food ingredients firm and a license deal with Phibro for animal vaccines. Positive developments include advancing a first-in-human clinical trial application for the DYAI-100 COVID-19 vaccine in South Africa, while a C1-produced antibody showed efficacy against Omicron variants. Cash and investments stood at $17.5 million as of March 31, 2022, against a net loss of approximately $2.49 million.

Dyadic International, Inc. (NASDAQ: DYAI) has entered into a Joint Development Agreement with a Global Food Ingredients Company to produce animal-free ingredient products. The project is fully funded with €3.6 million. Dyadic will develop proprietary production cell lines and can earn success and commercialization fees, along with royalties on sales. This partnership illustrates Dyadic's capacity to leverage its C1 protein production platform beyond biopharmaceuticals, tapping into emerging markets and enhancing its value in biomanufacturing.